Biocept Share Count Growth

What does Biocept do? Biocept, Inc. generates revenue through its oncology laboratory services, focusing on the detection of rare cells such as circulating tumor cells. The company markets its CNSide brand, which includes a suite of cellular and molecular technologies for central nervous system disease management. Its diagnostic assays, such as cell capture and enumeration, immunocytochemistry, FISH, and NGS, are commercialized for detecting various carcinomas and melanoma in blood and cerebrospinal fluid. Medical professionals and healthcare providers purchase these services to aid in patient diagnosis and treatment management. The CNSide product suite is designed for use in cerebrospinal fluid analysis, targeting solid tumor patients. Biocept's assays are specifically tailored for identifying rare tumor cells and cell-free tumor DNA, supporting clinical decision-making. The company's focus on solid tumors and CNS disease management positions it within the diagnostic laboratory services market, where healthcare institutions seek advanced tools for oncology care. Biocept's commercialized assays include cell capture, enumeration, immunocytochemistry, FISH, and NGS, all under the CNSide brand. These products are sold to medical professionals who require precise diagnostic tools for central nervous system disease management. The company's offerings are targeted at healthcare providers managing patients with solid tumors, particularly those requiring CSF analysis for disease monitoring and treatment planning. Biocept is one of the most popular companies on Eulerpool.